5 minutes | Dec 10th 2019

TULIP 1 - highlights from the ACR meeting

TULIP 1: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus

In this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.

Play Next
Mark Played